Wechselwirkungen von Pemetrexed

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Celecoxib, Arzneimittelwechselwirkungen)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Diclofenac, Arzneimittelwechselwirkungen)

Avoid diclofenac sodium/misoprostol for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Diclofenac und Misoprostol, Arzneimittelwechselwirkungen)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Fenoprofen, Arzneimittelwechselwirkungen)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Flurbiprofen, Arzneimittelwechselwirkungen)

In patients with creatinine clearances between 45 mL/min and 79 mL/min, avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of PEMFEXY. (Fachinformation zu Pemetrexed, Warnhinweise und Vorsichtsmaßnahmen)

In patients with creatinine clearances between 45 mL/min and 79 mL/min, avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of PEMFEXY. (Fachinformation zu Pemetrexed, Warnhinweise und Vorsichtsmaßnahmen)

In patients with creatinine clearances between 45 mL/min and 79 mL/min, avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of PEMFEXY. (Fachinformation zu Pemetrexed, Warnhinweise und Vorsichtsmaßnahmen)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Indometacin, Arzneimittelwechselwirkungen)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Mefenaminsäure, Arzneimittelwechselwirkungen)

In patients with creatinine clearance below 45 mL/min, the concomitant administration of meloxicam with pemetrexed is not recommended. (Fachinformation zu Meloxicam, Arzneimittelwechselwirkungen)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Naproxen, Arzneimittelwechselwirkungen)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Oxaprozin, Arzneimittelwechselwirkungen)

In patients with creatinine clearances between 45 mL/min and 79 mL/min, avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of PEMFEXY. (Fachinformation zu Pemetrexed, Warnhinweise und Vorsichtsmaßnahmen)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

Dihydrofolate Reductase (DHFR) Inhibitors : Avoid concomitant use (e.g., trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (Fachinformation zu Sepiapterin, Arzneimittelwechselwirkungen)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Initiate supplementation with oral folic acid and intramuscular vitamin B 12 to reduce the severity of hematologic and gastrointestinal toxicity of PEMFEXY. (Fachinformation zu Pemetrexed, Warnhinweise und Vorsichtsmaßnahmen)

Pemetrexed Clinical Impact : Concomitant use of naproxen and esomeprazole magnesium delayed-release tablets and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information). (Fachinformation zu Naproxen und Esomeprazol, Arzneimittelwechselwirkungen)

Clinical trials of VOTRIENT in combination with pemetrexed and lapatinib were terminated early due to increased toxicity and mortality. (Fachinformation zu Pazopanib, Warnhinweise und Vorsichtsmaßnahmen)

Initiate supplementation with oral folic acid and intramuscular vitamin B 12 to reduce the severity of hematologic and gastrointestinal toxicity of PEMFEXY. (Fachinformation zu Pemetrexed, Warnhinweise und Vorsichtsmaßnahmen)

…(38% versus 23%), thrombocytopenia (9% versus 5%), febrile neutropenia (9% versus 0.6%), and neutropenic infection (6% versus 0) were higher in patients who received pemetrexed plus cisplatin without vitamin supplementation as compared to patients who were fully supplemented with folic acid and vitamin B 12 prior to and throughout pemetrexed plus cisplatin treatment. (Fachinformation zu Pemetrexed, Warnhinweise und Vorsichtsmaßnahmen)